The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma is an aggressive malignancy with limited therapeutic options. MEK inhibition and antiangiogenic therapies have individually shown modest activity in advanced cholangiocarcinoma, whereas dual inhibition of these pathways has not been previously evaluated. We evaluated t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520097/
https://ncbi.nlm.nih.gov/pubmed/28441383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.119
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados